Shilpa Medicare`s marketing partner, Amneal Pharmaceuticals, has launched PEMRYDI RTU� (Pemetrexed injection 10 mg/mL), the first ready-to-use pemetrexed formulation in the US market. The product has already been granted permanent J-code (J9324) by U.S. Centers for Medicare & Medicaid Services (CMS). Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents. It is also indicated in the treatment of mesothelioma in combination with cisplatin. PEMRYDI RTU� is a novel ready-to-use injection which eliminates the need for refrigeration or reconstitution and dilution for administration to the patient. This offers hospitals and oncology clinics a new, value-added presentation that should improve pharmacy efficiency by eliminating preparation steps and freeing up refrigerator space. Currently product is available in two vial sizes: 100mg/10mL and 500 mg/50mL, and we intend to introduce 1000mg/100mL soon in the market. According to IQVIA�, U.S. annual sales for pemetrexed for the 12 months ended February 2024 were $287 million.Powered by Capital Market - Live News

Shilpa Medicare has allotted 1,09,89,010 equity shares of face value of Re 1 each to qualified institutional buyers at an issue price of Rs 455 per equity share I.e. at a premium of Rs 454 per equity share aggregating to Rs 499.99 crore pursuant to the qualified institutional placement issue. Pursuant to the allotment, the paid up equity share capital has increased to Rs 9,77,90,908, comprising of 9,77,90,908 equity shares of face value of Rs 1 each. Powered by Capital Market - Live News

Shilpa Medicare, headquartered at Raichur, Karnataka, India, has received closure of Decentralized Procedure for Varenicline Tablets, 0.5 mg and 1 mg. Commercial supplies shall be started after the approval of National Procedure. Varenicline is indicated for smoking cessation in adults. It is used for quitting smoking. This product had sales of about 57 Million USD as of December 2021 prior to a decline in sales due to drug shortage due to post-production quality issues. This approval will enable Shilpa to make this quality medicine available to adults who intend to quit smoking and fill the drug shortage.Powered by Capital Market - Live News

Net profit of Shilpa Medicare reported to Rs 4.58 crore in the quarter ended December 2023 as against net loss of Rs 6.62 crore during the previous quarter ended December 2022. Sales rose 9.14% to Rs 286.48 crore in the quarter ended December 2023 as against Rs 262.50 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales286.48262.50 9 OPM %22.6511.92 - PBDT40.8716.50 148 PBT14.17-7.58 LP NP4.58-6.62 LP Powered by Capital Market - Live News

Net profit of Shilpa Medicare reported to Rs 2.70 crore in the quarter ended December 2023 as against net loss of Rs 4.79 crore during the previous quarter ended December 2022. Sales rose 23.90% to Rs 63.98 crore in the quarter ended December 2023 as against Rs 51.64 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales63.9851.64 24 OPM %-5.16-19.87 - PBDT16.420.70 2246 PBT4.03-11.56 LP NP2.70-4.79 LP Powered by Capital Market - Live News